源语言 | 英语 |
---|---|
文章编号 | 100533 |
期刊 | The Lancet Regional Health - Europe |
卷 | 23 |
DOI | |
出版状态 | 已出版 - 12月 2022 |
已对外发布 | 是 |
!!!ASJC Scopus Subject Areas
- 内科学
- 肿瘤学
- 卫生政策
联合国可持续发展目标
此成果有助于实现下列可持续发展目标:
访问文件
其它文件与链接
引用此
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
在: The Lancet Regional Health - Europe, 卷 23, 100533, 12.2022.
科研成果: 期刊稿件 › 快报 › 同行评审
}
TY - JOUR
T1 - Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland
AU - Kerr, Steven
AU - Robertson, Chris
AU - Hillman, Sam
AU - Grange, Zoe
AU - Sullivan, Christopher
AU - Sheikh, Aziz
N1 - Funding Information: This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (MC_PC_20058). Additional support has been provided through Public Health Scotland, the Scottish Government Director General Health and Social Care, and the University of Edinburgh. The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK Government. We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available, and Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK) for their support with project management and administration. Funding Information: This study is part of the EAVE II project. EAVE II is funded by the MRC ( MC_PC_19075 ) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation ( MC_PC_20058 ). Additional support has been provided through Public Health Scotland , the Scottish Government Director General Health and Social Care, and the University of Edinburgh . The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK Government. We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available, and Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK) for their support with project management and administration.
PY - 2022/12
Y1 - 2022/12
UR - http://www.scopus.com/inward/record.url?scp=85141698840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141698840&partnerID=8YFLogxK
U2 - 10.1016/j.lanepe.2022.100533
DO - 10.1016/j.lanepe.2022.100533
M3 - Letter
AN - SCOPUS:85141698840
SN - 2666-7762
VL - 23
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
M1 - 100533
ER -